Bathi resik saben saham (EPS TTM): Verrica (VRCA)

Logo perusahaan publik verrica.com (VRCA)

Verrica Pharmaceuticals (VRCA) management strictly controls capital expenditure due to its reliance on the R&D pipeline. The trailing 12-month earnings per share snapshot illustrates the results of this strategy, where the -2.25 mark characterizes this parameter. Revenues are based on YCANTH sales, while exclusive patents for treating skin infections provide the company with a multi-year monopoly in the dermatological segment.

VRCA Bathi saben saham sajrone 12 wulan pungkasan verrica.com (04.07.2022 - 18.11.2026)

Rincian analitis lan laporan data perusahaan Verrica Pharmaceuticals (VRCA)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis umum perusahaan:VRCA - Verrica
Produk sing diprodhuksi Verrica

Verrica Pharmaceuticals (VRCA) is developing its dermato-oncology pipeline and expanding the distribution of treatments for contagious molluscum to mitigate operational risks. The EPS TTM metric measures net income allocated per share over the last twelve months. It reflects the actual return on equity, excluding the impact of the total number of securities. It is crucial for investors to see the true value of the business through this indicator during periods of price stagnation. Analyzing the trailing twelve-month earnings per share allows for the identification of the hidden accumulation of fundamental strengths.